Advertisement
New Zealand markets close in 2 hours 59 minutes
  • NZX 50

    11,850.98
    -16.31 (-0.14%)
     
  • NZD/USD

    0.6183
    -0.0010 (-0.16%)
     
  • NZD/EUR

    0.5666
    -0.0007 (-0.12%)
     
  • ALL ORDS

    8,009.30
    -14.80 (-0.18%)
     
  • ASX 200

    7,752.20
    -8.80 (-0.11%)
     
  • OIL

    73.65
    -0.57 (-0.77%)
     
  • GOLD

    2,365.90
    -3.40 (-0.14%)
     
  • NASDAQ

    18,600.97
    +64.32 (+0.35%)
     
  • FTSE

    8,262.75
    -12.63 (-0.15%)
     
  • Dow Jones

    38,571.03
    -115.29 (-0.30%)
     
  • DAX

    18,608.16
    +110.22 (+0.60%)
     
  • Hang Seng

    18,402.32
    -0.72 (-0.00%)
     
  • NIKKEI 225

    38,675.07
    -247.96 (-0.64%)
     
  • NZD/JPY

    96.7000
    +0.0600 (+0.06%)
     

Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ADELAIDE, Australia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual J.P. Morgan Healthcare Conference as follows:

Date:

Thursday, January 11, 2024

Time:

7:30am PST / 10:30 am EST

Webcast:

Click here

The live and archived webcast of the presentation will be accessible from the Company’s website www.maynepharma.com under Investor Relations. The replay of the webcast will be accessible for 30 days.

To schedule a 1x1 meeting with the Company, please contact 1x1@jpmorgan.com.

ADVERTISEMENT

For further information contact:

Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com

USA:
Lisa M. Wilson
+917 543 9932
ir@maynepharma.com

Authorised for release to the ASX by the Board

About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40- year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit https://www.maynepharma.com/.